Search

Search Constraints

You searched for: Author/Creator Fazio, N

Search Results

1. 1308OActivity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). (23rd October 2018)

2. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. (13th August 2019)

4. Clinico–pathological features, treatments and survival of malignant insulinomas: a multicenter study. Issue 4 (April 2020)

5. Clinico–pathological features, treatments and survival of malignant insulinomas: a multicenter study. Issue 4 (April 2020)